Homegrown pharma major Cipla Ltd on Tuesday (November 17) said the United States Food and Drug Administration (USFDA) has classified the inspection of its wholly owned subsidiary InvaGen Pharmaceuticals Inc.’s manufacturing facility in Hauppauge, Long Island, New York, as No Action Indicated (NAI).
The USFDA communicated the classification on November 17, 2026, following an inspection conducted at the facility from October 19 to October 22, 2026. Cipla had informed the stock exchanges about the inspection on October 23, 2026.
What is No Action Indicated (NAI)?
Given if no violations were observed. The facility can continue selling approved drugs and will also receive approvals for new filings.
ALSO READ | Cipla Q2 Results: US sales meet expectations, margins narrow from last year
Yesterday, Cipla said the Directorate of Revenue Intelligence (DRI), Mumbai Zonal Unit, conducted search proceedings at its office in Vikhroli, Mumbai, and depot in Bhiwandi, Thane, Maharashtra, in connection with the classification and exemption of an imported pharmaceutical finished product.
“…we hereby notify that the Directorate of Revenue Intelligence, Mumbai zonal unit, on 16 November 2026 conducted a search proceeding at the Company’s office located in Vikhroli, Mumbai, Maharashtra and at its depot located in Bhiwandi, Thane, Maharashtra. The Company extended its full co-operation and assistance in this regard,” according to a stock exchange filing.
The search was initiated and concluded on November 16 under Section 105 of the Customs Act, 1962, the pharmaceutical company said.
ALSO READ | Deven Choksey prefers Sun Pharma, Cipla for fresh buying; sees upside in Indian IT
Cipla said it extended full cooperation and assistance to the authorities during the proceedings. The company added that the search would have no material impact on its financials, operations or other activities.
Shares of Cipla Ltd ended at ₹232.60, down by ₹11.00, or 0.79%, on the BSE.
